-
Je něco špatně v tomto záznamu ?
Comorbidities and survival in patients with chronic hypersensitivity pneumonitis
J. Wälscher, B. Gross, J. Morisset, KA. Johannson, M. Vasakova, J. Bruhwyler, M. Kreuter,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2000-01-04
BioMedCentral Open Access
od 2000
Directory of Open Access Journals
od 2000
Free Medical Journals
od 2000
PubMed Central
od 2000
Europe PubMed Central
od 2000
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2000-06-01
Medline Complete (EBSCOhost)
od 2000-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
Springer Nature OA/Free Journals
od 2000-04-01
- MeSH
- bronchiální astma diagnóza mortalita MeSH
- chronická nemoc MeSH
- hypersenzitivní pneumonitida diagnóza mortalita MeSH
- komorbidita MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití trendy MeSH
- nádory plic diagnóza mortalita MeSH
- následné studie MeSH
- plicní hypertenze diagnóza mortalita MeSH
- prospektivní studie MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
INTRODUCTION: Chronic Hypersensitivity Pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from repeated exposure to an offending antigen. Prognostication in cHP remains challenging, and the relationship between comorbidities and survival has yet to be characterized. The aim of this study was to describe the relationship between comorbid conditions and survival in patients with cHP. METHODS: The prospective database from a tertiary referral centre for ILD was reviewed for patient-reported comorbidities, their frequency, and relationship with survival in cHP patients. Comorbidities were assessed by direct questioning of the patient at the baseline visit and by a standardized questionnaire for the diagnosis of interstitial lung diseases. During the follow-up examinations, patients were asked about newly diagnosed comorbidities. RESULTS: Two hundred eleven patients with cHP were identified (mean age 63 years, 53% male, mean FVC 73%), with mean follow-up of 32 months. The mean number of comorbidities was 3 (10% had 0, 59% 1-3 and 31% ≥4 comorbidities). Most frequent comorbidities groups were cardiovascular (65%) and respiratory (26%), most common comorbidities were hypertension (56%), gastro-esophageal reflux disease (GERD) (24%), diabetes (20%) and coronary heart disease (18%). In general, deceased patients had more comorbidities than survivors (p = 0.005), yet there was no association between the absolute number of comorbidities and survival. Pulmonary hypertension (30.8% versus 5.7%, p = 0.001;), diastolic dysfunction (26.9% versus 6.4%, p = 0.004) and cerebrovascular disease were more frequent in non-survivors (23.1% versus 7.6%, p = 0.026). Lung cancer was not observed, and neither GERD nor antacid drugs were associated with outcome (p = 0.357 and p = 0.961, respectively). CONCLUSIONS: Comorbidities are common in cHP are associated with survival. Further work should determine whether interventions for these specific comorbidities can positively affect survival.
Centre Hospitalier de l'Universite de Montreal Quebec Canada
Department of Medicine University of Calgary Medicine Calgary Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028609
- 003
- CZ-PrNML
- 005
- 20210114154433.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12931-020-1283-8 $2 doi
- 035 __
- $a (PubMed)31918716
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Wälscher, Julia $u Centre for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Röntgenstr. 1, D-69126, Heidelberg, Germany.
- 245 10
- $a Comorbidities and survival in patients with chronic hypersensitivity pneumonitis / $c J. Wälscher, B. Gross, J. Morisset, KA. Johannson, M. Vasakova, J. Bruhwyler, M. Kreuter,
- 520 9_
- $a INTRODUCTION: Chronic Hypersensitivity Pneumonitis (cHP) is a fibrotic interstitial lung disease (ILD) resulting from repeated exposure to an offending antigen. Prognostication in cHP remains challenging, and the relationship between comorbidities and survival has yet to be characterized. The aim of this study was to describe the relationship between comorbid conditions and survival in patients with cHP. METHODS: The prospective database from a tertiary referral centre for ILD was reviewed for patient-reported comorbidities, their frequency, and relationship with survival in cHP patients. Comorbidities were assessed by direct questioning of the patient at the baseline visit and by a standardized questionnaire for the diagnosis of interstitial lung diseases. During the follow-up examinations, patients were asked about newly diagnosed comorbidities. RESULTS: Two hundred eleven patients with cHP were identified (mean age 63 years, 53% male, mean FVC 73%), with mean follow-up of 32 months. The mean number of comorbidities was 3 (10% had 0, 59% 1-3 and 31% ≥4 comorbidities). Most frequent comorbidities groups were cardiovascular (65%) and respiratory (26%), most common comorbidities were hypertension (56%), gastro-esophageal reflux disease (GERD) (24%), diabetes (20%) and coronary heart disease (18%). In general, deceased patients had more comorbidities than survivors (p = 0.005), yet there was no association between the absolute number of comorbidities and survival. Pulmonary hypertension (30.8% versus 5.7%, p = 0.001;), diastolic dysfunction (26.9% versus 6.4%, p = 0.004) and cerebrovascular disease were more frequent in non-survivors (23.1% versus 7.6%, p = 0.026). Lung cancer was not observed, and neither GERD nor antacid drugs were associated with outcome (p = 0.357 and p = 0.961, respectively). CONCLUSIONS: Comorbidities are common in cHP are associated with survival. Further work should determine whether interventions for these specific comorbidities can positively affect survival.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a hypersenzitivní pneumonitida $x diagnóza $x mortalita $7 D000542
- 650 _2
- $a bronchiální astma $x diagnóza $x mortalita $7 D001249
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plicní hypertenze $x diagnóza $x mortalita $7 D006976
- 650 _2
- $a nádory plic $x diagnóza $x mortalita $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $x trendy $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gross, Benjamin $u Centre for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Röntgenstr. 1, D-69126, Heidelberg, Germany.
- 700 1_
- $a Morisset, Julie $u Centre Hospitalier de l'Universite de Montreal, Quebec, Canada.
- 700 1_
- $a Johannson, Kerri A $u Department of Medicine, University of Calgary, Medicine, Calgary, Canada.
- 700 1_
- $a Vasakova, Martina $u Department of Respiratory Medicine, First Faculty of Medicine of Charles University, Thomayer Hospital, Prague, Czech Republic.
- 700 1_
- $a Bruhwyler, Jacques $u ECSOR Department of Biostatistics, Gembloux, Belgium.
- 700 1_
- $a Kreuter, Michael $u Centre for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Röntgenstr. 1, D-69126, Heidelberg, Germany. kreuter@uni-heidelberg.de. German Center for Lung Research, Heidelberg, Germany. kreuter@uni-heidelberg.de.
- 773 0_
- $w MED00006600 $t Respiratory research $x 1465-993X $g Roč. 21, č. 1 (2020), s. 12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31918716 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154429 $b ABA008
- 999 __
- $a ok $b bmc $g 1608944 $s 1119789
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 1 $d 12 $e 20200109 $i 1465-993X $m Respiratory research $n Respir Res $x MED00006600
- LZP __
- $a Pubmed-20210105